納洛酮市場按強度、給藥途徑、分銷管道和地區分類

2025 年全球納洛酮市場規模估計為 14.838 億美元，預計到 2032 年將達到 30.057 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 10.6%。

數字。 2025 年納洛酮各地區市場佔有率（%）

納洛酮是一種鴉片類藥物拮抗劑，用於完全或部分逆轉鴉片類藥物過量攝取。它的工作原理是競爭性地與鴉片受體結合，逆轉或阻斷其他鴉片類藥物的作用。納洛酮已成為鴉片類藥物過量攝取緊急醫療的重要組成部分。全球許多地區正經歷持續的鴉片類藥物危機，鴉片類藥物濫用現象近期急劇增加。因此，對於緊急治療所需的易獲得的納洛酮製劑的需求日益增加。預計這一因素將對未來幾年全球納洛酮市場的成長軌跡產生重大影響。

市場動態

全球納洛酮市場主要受到全球鴉片類藥物過量攝取案例增加的推動。美國美國藥物濫用實驗室的數據顯示，2000年至2020年間，美國鴉片類藥物過量攝取死亡率上升了130%以上。此外，新冠肺炎疫情加劇了社會隔離對心理健康的影響，導致許多國家鴉片類藥物濫用現象增加。醫療保健和執法機構對易於使用的納洛酮輸送製劑（如滴鼻劑和自動注射器）的需求很高，這推動了市場成長。然而，納洛酮治療的副作用和替代治療方案的可用性限制了市場的擴張。正在進行的長效納洛酮製劑研發將為未來的主要企業提供豐厚的機會。

研究的主要特點

• 本報告對全球納洛酮市場進行了詳細分析，並提供了預測期（2025-2032）的市場規模和年複合成長率（CAGR%），假設 2024 年為基準年。
• 它還強調了各個領域的潛在收益成長機會，並說明了該市場的引人注目的投資提案矩陣。
• 它還提供了關於市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的主要考察。
• 它根據公司亮點、產品系列、關鍵亮點、財務業績和策略等參數，對全球納洛酮市場的主要企業進行了概述。
• 本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
• 本研究報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
• 相關人員將透過全球納洛酮市場分析中使用的各種策略矩陣更輕鬆地做出決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場概況

• 報告描述
  • 市場定義和範圍
• 執行摘要
• 一致的機會圖 (COM)

第3章市場動態、法規與趨勢分析

• 市場動態
• 影響分析
• 波特的分析
• 產業趨勢
• 流行病學
• 贖回情況
• 監管情景
• 產品發布和核准
• 收購和合作場景

4. 全球納洛酮市場 - 冠狀病毒 (COVID-19) 大流行的影響

• COVID-19 流行病學
• COVID-19 對納洛酮供需的影響
• COVID-19 對整個醫療產業的影響

5. 全球納洛酮市場，依實力分類，2020 年至 2032 年

• 介紹
• 2.0mg/ml
• 1mg/ml
• 0.4mg/ml
• 其他

6. 2020 年至 2032 年按給藥途徑分類的全球納洛酮市場

• 介紹
• 鼻腔內
• 注射
• 肌肉注射
• 皮下
• 靜脈

7. 2020 年至 2032 年全球納洛酮市場按分銷管道分類

• 介紹
• 醫院藥房
• 零售藥局
• 網路藥局

8. 2020 年至 2032 年全球納洛酮市場（按地區）

• 介紹
• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 非洲

第9章 競爭格局

• 公司簡介
  • Viatris Inc.
  • Opiant Pharmaceuticals
  • Akorn Operating Company LLC
  • Pfizer, Inc.
  • Novartis AG
  • Indivior Plc.
  • Emergent BioSolutions Inc.
  • Amphastar Pharmaceuticals, Inc.
  • Kern Pharma, SL
  • Hikma Pharmaceuticals PLC
  • Mundipharma International Limited
  • Kaleo, Inc.
  • Pfizer Inc.
  • Amneal Pharmaceuticals
  • Viatris Inc.
  • Somerset Pharma, LLC
  • Orexo AB
  • UCB Pharma

第 10 章 分析師觀點

• 興衰
• 一致的機會地圖

第 11 章 參考文獻與調查方法

• 參考
• 調查方法

Global Naloxone Market is estimated to be valued at USD 1,483.8 Mn in 2025 and is expected to reach USD 3,005.7 Mn by 2032, growing at a compound annual growth rate (CAGR) of 10.6% from 2025 to 2032.

Figure. Naloxone Market Share (%), By Region 2025

Naloxone is an opioid antagonist used for the complete or partial reversal of opioid overdose. It works by competitively binding to opioid receptors and reversing and blocking the effects of other opiates. Naloxone has become an integral part of emergency medical treatment for opioid overdoses. With the ongoing opioid crisis in many parts of the world, the prevalence of opioid abuse has increased massively in recent times. As a result, the need for readily available naloxone formulations has grown for emergency treatment. This factor is expected to largely influence the growth trajectory of the global naloxone market in the coming years.

Market Dynamics:

The global naloxone market is primarily driven by the rising incidence of opioid overdose cases worldwide. According to the National Institute on Drug Abuse, opioid overdose mortality rates in the U.S. increased by over 130% between 2000 and 2020. Moreover, the COVID-19 pandemic further exacerbated the impact of social isolation on psychological health and increased opioid misuse in many countries. A high demand for user-friendly naloxone delivery formulations like nasal sprays and auto-injectors from both healthcare and law enforcement agencies is fueling the market growth. However, adverse side effects associated with naloxone therapy and the availability of alternative treatment options are limiting market expansion. Ongoing R&D into the development of long-acting naloxone formulations present lucrative opportunities for key players in the future.

Key Features of the Study:

• This report provides an in-depth analysis of the global naloxone market, and provides market size (US$ MN) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global naloxone market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes EMERGENT, Indivior PLC, Akorn, Inc, Hikma Pharmaceuticals PLC, Viatris Inc., Sandoz, Teva Pharmaceuticals, Amphastar Pharmaceuticals, Inc., Kaleo, Inc., Pfizer Inc., Amneal Pharmaceuticals, Viatris Inc., Somerset Pharma, LLC, Orexo AB, and UCB Pharma.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global naloxone market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global naloxone market.

Market Segmentation

• Strength:
  • 2.0 mg/ml
  • 1 mg/ml
  • 0.4 mg/ml
  • Others
• Route of Administration:
  • Intranasal
  • Injectable
  • Intramuscular
  • Subcutaneous
  • Intravenous
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • EMERGENT
  • Indivior PLC
  • Akorn, Inc
  • Hikma Pharmaceuticals PLC
  • Viatris Inc.
  • Sandoz
  • Teva Pharmaceuticals
  • Amphastar Pharmaceuticals, Inc.
  • Kaleo, Inc.
  • Pfizer Inc.
  • Amneal Pharmaceuticals
  • Viatris Inc.
  • Somerset Pharma, LLC
  • Orexo AB
  • UCB Pharma

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Naloxone Market, By Strength
  • Naloxone Market, By Route of Administration
  • Naloxone Market, By Distribution Channel
  • Naloxone Market, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Porter's Analysis
• Industry Trends
• Key Highlights
• Epidemiology
• Reimbursement Scenario
• Regulatory Scenario
• Product Launch and Approvals
• Acquisition and Collaboration Scenario

4. Global Naloxone Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Impact of COVID-19 on the Demand and Supply of Naloxone
• Impact of COVID-19 on the Overall Healthcare Sector

5. Global Naloxone Market, By Strength, 2020-2032 (USD MN)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020-2032
  • Segment Trends
• 2.0 mg/ml
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• 1mg/ml
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• 0.4 mg/ml
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)

6. Global Naloxone Market, By Route of Administration, 2020-2032 (USD MN)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020-2032
  • Segment Trends
• Intranasal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• Intramuscular
• Subcutaneous
• Intravenous

7. Global Naloxone Market, By Distribution Channel, 2020-2032 (USD MN)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020-2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)

8. Global Naloxone Market, By Region, 2020-2032 (USD MN)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Regions, 2020-2032
  • Regional Trends
• North America
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country, 2020-2032 (USD MN)
    • U.S.
    • Canada
• Latin America
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country, 2020-2032 (USD MN)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country, 2020-2032 (USD MN)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country, 2020-2032 (USD MN)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country, 2020-2032 (USD MN)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country/Region, 2020-2032 (USD MN)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

• Company Profiles
  • Viatris Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Opiant Pharmaceuticals
  • Akorn Operating Company LLC
  • Pfizer, Inc.
  • Novartis AG
  • Indivior Plc.
  • Emergent BioSolutions Inc.
  • Amphastar Pharmaceuticals, Inc.
  • Kern Pharma, S.L.
  • Hikma Pharmaceuticals PLC
  • Mundipharma International Limited
  • Kaleo, Inc.
  • Pfizer Inc.
  • Amneal Pharmaceuticals
  • Viatris Inc.
  • Somerset Pharma, LLC
  • Orexo AB
  • UCB Pharma

10. Analyst View

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact